Fisogatinib/BLU-554 is a selective oral FGFR4 inhibitor which was evaluated in a phase I dose escalation study in advanced HCC patients using FGF19 as a biomarker in immunohistochemical staining of the tumor [162]. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.